Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

In the published article, there was an error in Figure 1 as published. The figure itself including the proportion of changes is correct. However, the numbers representing percent changes in reduction of symptoms do not correspond to those mentioned in the text but rather to a preliminary calculation from a smaller cohort of patients. Noteworthy, the improvement in abdominal symptoms assessed with the CFAbd-Score during ETI is in fact markedly higher in the now corrected version. The corrected Figure 1 and its caption appear below.

FIGURE 1.

CFAbd-Score changes for the whole cohort and its 5 domains after therapy initiation (Table 1). Percent changes are calculated from estimated marginal means (EMMs) at week 24 of ETI therapy.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.